Zoledronate disodium | CAS#131654-46-1 | Osteoclastogenesis & macrophage recruitment inhibitor

MedKoo Cat#: 463607 | Name: Zoledronate disodium

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Zoledronate disodium is an inhibitor of osteoclastogenesis and macrophage recruitment, decreasing bone turnover and stabilizing the bone matrix, exhibiting diverse anti-tumor effects in osteosarcoma.

Chemical Structure

Zoledronate disodium

CAS#131654-46-1 (disodium)

Theoretical Analysis

MedKoo Cat#: 463607

Name: Zoledronate disodium

CAS#: 131654-46-1 (disodium)

Chemical Formula: C5H8N2Na2O7P2

Exact Mass:

Molecular Weight: 316.05

Elemental Analysis: C, 19.00; H, 2.55; N, 8.86; Na, 14.55; O, 35.43; P, 19.60

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

118072-93-8 (free acid) 165800-06-6 (free acid hydrate) 131654-46-1 (disodium) 827573-11-5 (trisodium) 165800-07-7 (disodium hydrate) 165800-08-8 (trisodium hydrate)

Synonym

Zoledronate disodium; CGP-42446A; CGP42446A; CGP 42446A;

IUPAC/Chemical Name

sodium (1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl)bis(hydrogen phosphonate)

InChi Key

OPQQEYHAVUNQNA-UHFFFAOYSA-L

InChi Code

InChI=1S/C5H10N2O7P2.2Na/c8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7;;/h1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14);;/q;2*+1/p-2

SMILES Code

O=P(C(P([O-])(O)=O)(O)CN1C=CN=C1)(O)[O-].[Na+].[Na+]

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 316.05 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Ralston SH. Bisphosphonates in the management of Paget's disease. Bone. 2020 Sep;138:115465. doi: 10.1016/j.bone.2020.115465. Epub 2020 Jun 5. PMID: 32512166. 2: Li P, Hu Y. "Turn-Off" Fluorescent Sensor for Pamidronate Disodium and Zoledronic Acid Based on Newly Synthesized Carbon Dots from Black Tea. J Anal Methods Chem. 2018 Mar 13;2018:3631249. doi: 10.1155/2018/3631249. PMID: 29725552; PMCID: PMC5872615. 3: Ong MWS, Jones L. Improving Bisphosphonate Infusion Monitoring at Haematology Medical Day Unit. BMJ Qual Improv Rep. 2017 Mar 31;6(1):u206586.w4692. doi: 10.1136/bmjquality.u206586.w4692. PMID: 28469896; PMCID: PMC5388016. 4: Hortobagyi GN, Van Poznak C, Harker WG, Gradishar WJ, Chew H, Dakhil SR, Haley BB, Sauter N, Mohanlal R, Zheng M, Lipton A. Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone: The OPTIMIZE-2 Randomized Clinical Trial. JAMA Oncol. 2017 Jul 1;3(7):906-912. doi: 10.1001/jamaoncol.2016.6316. PMID: 28125763; PMCID: PMC5824238. 5: Yang L, Du S. Efficacy and Safety of Zoledronic Acid and Pamidronate Disodium in the Treatment of Malignant Skeletal Metastasis: A Meta-Analysis. Medicine (Baltimore). 2015 Oct;94(42):e1822. doi: 10.1097/MD.0000000000001822. PMID: 26496320; PMCID: PMC4620752. 6: Seal B, Sullivan SD, Ramsey SD, Asche CV, Shermock K, Sarma S, Zagadailov EA, Farrelly E, Eaddy M. Comparing hospital-based resource utilization and costs for prostate cancer patients with and without bone metastases. Appl Health Econ Health Policy. 2014 Oct;12(5):547-57. doi: 10.1007/s40258-014-0101-1. PMID: 25005491; PMCID: PMC4175039. 7: Biernacka J, Betlejewska-Kielak K, Kłosińska-Szmurło E, Pluciński FA, Mazurek AP. Prediction of bioavailability of selected bisphosphonates using in silico methods towards categorization into a biopharmaceutical classification system. Acta Pol Pharm. 2013 Sep-Oct;70(5):877-82. PMID: 24147367. 8: De Ponte FS, Favaloro A, Siniscalchi EN, Centofanti A, Runci M, Cutroneo G, Catalfamo L. Sarcoglycans and integrins in bisphosphonate treatment: immunohistochemical and scanning electron microscopy study. Oncol Rep. 2013 Dec;30(6):2639-46. doi: 10.3892/or.2013.2766. Epub 2013 Oct 1. PMID: 24100935. 9: Faiman B, Pillai AL, Benghiac AG. Bisphosphonate-related osteonecrosis of the jaw: historical, ethical, and legal issues associated with prescribing. J Adv Pract Oncol. 2013 Jan;4(1):25-35. PMID: 25031978; PMCID: PMC4093372. 10: Henk HJ, Kaura S. Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan. J Med Econ. 2012;15(1):175-84. doi: 10.3111/13696998.2011.632044. Epub 2011 Nov 8. PMID: 22017235. 11: Vuorimies I, Toiviainen-Salo S, Hero M, Mäkitie O. Zoledronic acid treatment in children with osteogenesis imperfecta. Horm Res Paediatr. 2011;75(5):346-53. doi: 10.1159/000323368. Epub 2011 Feb 2. PMID: 21293106. 12: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2010 Jun;32(5):331-88. doi: 10.1358/mf.2010.32.5.1520420. PMID: 20664824. 13: Treeprasertsuk S, Silveira MG, Petz JL, Lindor KD. Parenteral bisphosphonates for osteoporosis in patients with primary biliary cirrhosis. Am J Ther. 2011 Sep;18(5):375-81. doi: 10.1097/MJT.0b013e3181d7e1d3. PMID: 20460985. 14: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2010 Apr;32(3):193-215. doi: 10.1358/mf.2010.32.3.1492017. PMID: 20448862. 15: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2009 Apr;31(3):183-226. PMID: 19536362. 16: Moral MA, Tomillero A. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008 Mar;30(2):149-71. PMID: 18560631. 17: Bayés M, Rabasseda X. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008 Jan-Feb;30(1):67-99. PMID: 18389098. 18: Brown JJ, Ramalingam L, Zacharin MR. Bisphosphonate-associated osteonecrosis of the jaw: does it occur in children? Clin Endocrinol (Oxf). 2008 Jun;68(6):863-7. doi: 10.1111/j.1365-2265.2008.03189.x. Epub 2008 Jan 21. PMID: 18221397. 19: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007 Dec;29(10):697-735. PMID: 18200333. 20: Heras Rincón I, Zubillaga Rodríguez I, Castrillo Tambay M, Montalvo Moreno JJ. Osteonecrosis of the jaws and bisphosphonates. Report of fifteen cases. Therapeutic recommendations. Med Oral Patol Oral Cir Bucal. 2007 Aug 1;12(4):E267-71. PMID: 17664910.